Fig 3. Dependence on age.

Those diagnosed before the age of 50 years are shown on the left (A, C, E) and those diagnosed at ≥50 years are shown on the right (B, D, F). There are fewer competing risks in younger vs older patients (A vs B), so the cross-over time is much later. Fewer competing risks in younger patients does not, however, imply a greater overall probability of death by melanoma, as final percentage are ~30% vs ~50% (C vs D). The reason is that the disease itself is less lethal in younger patients (E vs F).